Cargando…
Enrichment of SOX2-Positive Cells in BRAF V600E Mutated and Recurrent Ameloblastoma
Ameloblastoma is the most common benign odontogenic neoplasm, but with an aggressive behavior and a high recurrence rate. Nowadays wide surgical resection is the current recommended treatment, which can cause further loss of function and esthetics. Recent studies point to the stem/progenitor cells a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780877/ https://www.ncbi.nlm.nih.gov/pubmed/35055392 http://dx.doi.org/10.3390/jpm12010077 |
_version_ | 1784637952067895296 |
---|---|
author | Tseng, Chih-Huang Lu, Pei-Hsuan Wang, Yi-Ping Chang, Julia Yu Fong |
author_facet | Tseng, Chih-Huang Lu, Pei-Hsuan Wang, Yi-Ping Chang, Julia Yu Fong |
author_sort | Tseng, Chih-Huang |
collection | PubMed |
description | Ameloblastoma is the most common benign odontogenic neoplasm, but with an aggressive behavior and a high recurrence rate. Nowadays wide surgical resection is the current recommended treatment, which can cause further loss of function and esthetics. Recent studies point to the stem/progenitor cells as both initiators and propagators of the tumors. Elucidation of the cellular and molecular mechanisms underlying the tumor stem cells is of broad interest for understanding tumorigenesis and for developing effective targeted therapies. SRY related HMG box gene 2 (SOX2) is a transcription factor that plays important roles in development, stem cell renewal, and cancer formation. Few studies have revealed increased SOX2 expression in atypical ameloblastoma and ameloblastic carcinoma. For the development of personalized medicine for ameloblastoma, biomarkers that provide prognostic or predictive information regarding a tumor’s nature or its response to treatment are essential. Thus, in this study, we aimed to study if SOX2-positive cells exist in ameloblastomas and their correlation with the clinicopathologic parameters. Our data suggested BRAF(V600E) mutation might contribute to the expansion of SOX2-positive cells. The identification of BRAF(V600E) mutation and the amplification of SOX2-positive cells in ameloblastomas imply the possible benefit of applying BRAF and SOX2 inhibitors in recurrent and un-resectable ameloblastomas. |
format | Online Article Text |
id | pubmed-8780877 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87808772022-01-22 Enrichment of SOX2-Positive Cells in BRAF V600E Mutated and Recurrent Ameloblastoma Tseng, Chih-Huang Lu, Pei-Hsuan Wang, Yi-Ping Chang, Julia Yu Fong J Pers Med Article Ameloblastoma is the most common benign odontogenic neoplasm, but with an aggressive behavior and a high recurrence rate. Nowadays wide surgical resection is the current recommended treatment, which can cause further loss of function and esthetics. Recent studies point to the stem/progenitor cells as both initiators and propagators of the tumors. Elucidation of the cellular and molecular mechanisms underlying the tumor stem cells is of broad interest for understanding tumorigenesis and for developing effective targeted therapies. SRY related HMG box gene 2 (SOX2) is a transcription factor that plays important roles in development, stem cell renewal, and cancer formation. Few studies have revealed increased SOX2 expression in atypical ameloblastoma and ameloblastic carcinoma. For the development of personalized medicine for ameloblastoma, biomarkers that provide prognostic or predictive information regarding a tumor’s nature or its response to treatment are essential. Thus, in this study, we aimed to study if SOX2-positive cells exist in ameloblastomas and their correlation with the clinicopathologic parameters. Our data suggested BRAF(V600E) mutation might contribute to the expansion of SOX2-positive cells. The identification of BRAF(V600E) mutation and the amplification of SOX2-positive cells in ameloblastomas imply the possible benefit of applying BRAF and SOX2 inhibitors in recurrent and un-resectable ameloblastomas. MDPI 2022-01-08 /pmc/articles/PMC8780877/ /pubmed/35055392 http://dx.doi.org/10.3390/jpm12010077 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tseng, Chih-Huang Lu, Pei-Hsuan Wang, Yi-Ping Chang, Julia Yu Fong Enrichment of SOX2-Positive Cells in BRAF V600E Mutated and Recurrent Ameloblastoma |
title | Enrichment of SOX2-Positive Cells in BRAF V600E Mutated and Recurrent Ameloblastoma |
title_full | Enrichment of SOX2-Positive Cells in BRAF V600E Mutated and Recurrent Ameloblastoma |
title_fullStr | Enrichment of SOX2-Positive Cells in BRAF V600E Mutated and Recurrent Ameloblastoma |
title_full_unstemmed | Enrichment of SOX2-Positive Cells in BRAF V600E Mutated and Recurrent Ameloblastoma |
title_short | Enrichment of SOX2-Positive Cells in BRAF V600E Mutated and Recurrent Ameloblastoma |
title_sort | enrichment of sox2-positive cells in braf v600e mutated and recurrent ameloblastoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780877/ https://www.ncbi.nlm.nih.gov/pubmed/35055392 http://dx.doi.org/10.3390/jpm12010077 |
work_keys_str_mv | AT tsengchihhuang enrichmentofsox2positivecellsinbrafv600emutatedandrecurrentameloblastoma AT lupeihsuan enrichmentofsox2positivecellsinbrafv600emutatedandrecurrentameloblastoma AT wangyiping enrichmentofsox2positivecellsinbrafv600emutatedandrecurrentameloblastoma AT changjuliayufong enrichmentofsox2positivecellsinbrafv600emutatedandrecurrentameloblastoma |